Research programme: macrophage-1-antigen modulators - Sujana Biotech

Drug Profile

Research programme: macrophage-1-antigen modulators - Sujana Biotech

Alternative Names: Mac-1:GPIb alpha inhibitors - Sujana Biotech; Macrophage-1-antigen modulators - Sujana Biotech

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sujana Biotech
  • Class Anti-inflammatories; Monoclonal antibodies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants; Macrophage 1 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Inflammation; Vascular disorders

Most Recent Events

  • 01 Nov 2017 Macrophage-1-antigen modulators - Sujana Biotech is available for licensing as of 01 Nov 2017. http://www.sujanabio.com/partners/
  • 22 Sep 2017 Preclinical trials in Inflammation in USA (Parenteral) (Sujana Biotech pipeline)
  • 22 Sep 2017 Preclinical trials in Vascular diseases in USA (Parenteral) (Sujana Biotech pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top